Corvus Pharmaceuticals, Inc. (CRVS): Capital Expenditures
$174.0K
Year ended 2025-12-31
$698.0K
Trailing 12 months to 2026-06-30
-13.5%
3-year compound annual growth
+18.0%
5-year compound annual growth
-20.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $174.0K | n/a | 2026-03-12, From 2025-01-01 |
| No annual figure between 2023-12-31 and 2025-12-31. | |||
| 2023-12-31 | $34.0K | -87.4% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $269.0K | n/m | 2025-03-25, From 2022-01-01 |
| 2021-12-31 | $5.0K | -93.4% | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | $76.0K | +204.0% | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | $25.0K | -93.0% | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | $355.0K | +33.5% | 2021-03-25, From 2018-01-01 |
| 2017-12-31 | $266.0K | -87.9% | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | $2.20M | +25.9% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $1.75M | n/a | 2018-03-01, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $174.0K | n/a |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $0 | -100.0% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $33.9K | +364.0% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $285.7K | -41.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Rallybio Corp (RLYB) | 2024-12-31 | $0 | -100.0% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.50M | +48.3% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $46.0K | -11.5% |
Compare CRVS, HOWL, CNTX, INO side by side · Screen every company in Pharmaceutical Preparations ↗